ClinicalTrials.gg
CompletedNCT00774800Updated Feb 26, 2019Results posted

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

A Phase 2 interventional study of Humalog and Humulin-R in Type 1 Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Halozyme Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
51st of 69
22 · median 38
Started
2008
with 2 others
Phase 2
7 of 69
none open now
Registered
10th of 69
by date
Lead sponsor
4 of 69
Halozyme Therapeutics

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 51st largest by enrollment, is one of 3 that started in 2008, is one of 7 in phase 2, and was the 10th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with both Humalog and Humulin-R in order to determine if it improves the absorption of these insulins to more closely mimic the body's natural increase in insulin in response to a meal.

Read the detailed description

Participants received all 4 interventions in the same order.

Dose-finding visits were conducted to identify the appropriate dose of Humalog and Humulin-R. For each Humalog dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). For each Humulin-R dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humulin-R, corresponding to a mass concentration of 20.0 μg/mL rHuPH20 (at final concentration of 100 U/mL of Humulin-R).

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Recombinant Hyaluronidase
  • Type 1 Diabetes Mellitus
  • Humalog
  • Humulin R
  • rHuPH20
  • Hylenex
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of age 18 to 65 years, inclusive. Females of must use a standard and effective means of for the duration of the study.
  • Participants with Type 1 diabetes mellitus treated with insulin for greater than or equal to 12 months.
  • (BMI) 18.0 to 29.0 kilograms per meter squared (kg/m\^2), inclusive.
  • Glycosylated (HbA1c) less than or equal to 10% based on local laboratory results.
  • Fasting C-peptide less than 0.6 nanograms per milliliter (ng/mL).
  • Current treatment with insulin less than 1.2 units per kilogram per day (U/kg/day).
  • Participants should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug injections and assessments required in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to any component of any of the study drugs in this trial.
  • Previous enrollment in this trial.
  • A participant who has proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.
  • (as judged by the Investigator) active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on [ECG]), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure greater than or equal to 100 millimeters of mercury [mmHg] and/or systolic blood pressure greater than or equal to 160 mmHg after 5 minutes in the supine position).
  • History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the participant.
  • Clinically significant findings (as judged by the Investigator) in routine laboratory data, including anemia with less than lower limits of normal at screening.
  • Use of drugs which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia.
  • Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator.
  • Current addiction to alcohol or substances of abuse as determined by the Investigator.
  • Blood donation (>500 milliliters [mL]) within the 9 weeks prior to first day of dosing on study.
  • Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives or barrier methods).
  • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation.
  • Symptomatic gastroparesis.
  • History or evidence of use of any tobacco- or nicotine-containing product within 6 months of screening or screening quantitative urine nicotine concentration >50 ng/mL.
  • Receipt of any drug within 4 weeks of first day of dosing in this study.
  • Any condition (intrinsic or extrinsic) that in the judgment of the Investigator will interfere with trial participation or evaluation of data.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R

    Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified. Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal. Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified. Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal. Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was \<160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL. All dose finding visits and interventions were separated by 3-10 days.

    Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20) · Other: Liquid meal

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)

    AUC was derived as the area under the serum insulin concentration profile from 0 to time "t." Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; and at 20, 30, 45, and 60 mins postdose.

    Time frame: Predose up to 60 minutes postdose

Secondary outcomes

  1. Maximum Serum Insulin Concentration (Cmax)

    Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.

    Time frame: Predose up to 480 minutes postdose

  2. Time to Maximum Serum Insulin Concentration (Tmax)

    Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.

    Time frame: Predose up to 480 minutes postdose

  3. Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG])

    AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 140 milligrams per deciliter (mg/dL) within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before; at 3, 6, 9, 12, 15, 20, 25 minutes; and every 10 minutes from minute 30 to 240 postdose.

    Time frame: Predose up to 4 hours after injection of study drug

07

Results

Posted Sep 5, 2014

Participant flow

Intervention 1
Participant flow — Intervention 1
MilestoneFirst Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
Started22
Received at least one dose of study drug22
Completed22
Not completed0
Washout (3 to 10 Days)
Participant flow — Washout (3 to 10 Days)
MilestoneFirst Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
Started22
Completed22
Not completed0
Intervention 2
Participant flow — Intervention 2
MilestoneFirst Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
Started22
Received at least one dose of study drug22
Completed22
Not completed0
Washout (3 to 10 Days)
Participant flow — Washout (3 to 10 Days)
MilestoneFirst Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
Started22
Completed22
Not completed0
Intervention 3
Participant flow — Intervention 3
MilestoneFirst Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
Started22
Received at least one dose of study drug22
Completed22
Not completed0
Washout (3 to 10 Days)
Participant flow — Washout (3 to 10 Days)
MilestoneFirst Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
Started22
Completed22
Not completed0
Intervention 4
Participant flow — Intervention 4
MilestoneFirst Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
Started22
Received at least one dose of study drug21
Completed21
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryArea Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)

AUC was derived as the area under the serum insulin concentration profile from 0 to time "t." Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; and at 20, 30, 45, and 60 mins postdose.

Time frame:
Predose up to 60 minutes postdose
Reported as:
Mean · nanomole*minute per liter (nmol*min/L)
Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)
nanomole*minute per liter (nmol*min/L)Humalog + rHuPH20Humalog AloneHumulin-R + rHuPH20Humulin-R Alone
Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)12346.67 ± 4996.798297.62 ± 3670.0311607.65 ± 6770.614331.76 ± 3068.10
Statistical analysis
  • Humalog + rHuPH20 vs Humalog Alone · ANOVA · p = 0.0011 (Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.) · Geometric least squares means ratio: 1.54
  • Humulin-R + rHuPH20 vs Humulin-R Alone · ANOVA · p = <0.0001 (Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.) · Geometric least squares means ratio: 3.06
SecondaryMaximum Serum Insulin Concentration (Cmax)

Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.

Time frame:
Predose up to 480 minutes postdose
Reported as:
Mean · Picomoles per liter (pmol/L)
Maximum Serum Insulin Concentration (Cmax)
Picomoles per liter (pmol/L)Humalog + rHuPH20Humalog AloneHumulin-R + rHuPH20Humulin-R Alone
Maximum Serum Insulin Concentration (Cmax)307.67 ± 125.73226.38 ± 85.51285.88 ± 139.54165.05 ± 68.98
Statistical analysis
  • Humalog + rHuPH20 vs Humalog Alone · ANOVA · p = 0.0057 (Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.) · Geometric least squares means ratio: 1.35
  • Humulin-R + rHuPH20 vs Humulin-R Alone · ANOVA · p = <0.0001 (Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.) · Geometric least squares means ratio: 1.66
SecondaryTime to Maximum Serum Insulin Concentration (Tmax)

Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.

Time frame:
Predose up to 480 minutes postdose
Reported as:
Mean · minutes
Time to Maximum Serum Insulin Concentration (Tmax)
minutesHumalog + rHuPH20Humalog AloneHumulin-R + rHuPH20Humulin-R Alone
Time to Maximum Serum Insulin Concentration (Tmax)30.24 ± 8.7348.57 ± 13.3457.06 ± 30.83116.76 ± 65.02
Statistical analysis
  • Humalog + rHuPH20 vs Humalog Alone · ANOVA · p = <0.0001 (Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.) · Least squares means difference: -18.33
  • Humulin-R + rHuPH20 vs Humulin-R Alone · ANOVA · p = 0.0018 · Least squares means difference: -62.46Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.
SecondaryArea Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG])

AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 140 milligrams per deciliter (mg/dL) within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before; at 3, 6, 9, 12, 15, 20, 25 minutes; and every 10 minutes from minute 30 to 240 postdose.

Time frame:
Predose up to 4 hours after injection of study drug
Reported as:
Geometric mean · minutes*milligrams per deciliter
Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG])
minutes*milligrams per deciliterHumalog + rHuPH20Humalog AloneHumulin-R + rHuPH20Humulin-R Alone
Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG])111 (35 to 357)526 (164 to 1685)181 (57 to 581)1,238 (343 to 4466)

Adverse events

Collected over Adverse event data collected from Day 1 through to the end of the study, for up to 80 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Humalog + rHuPH20—0/22 (0%)14/22 (63.6%)
Humalog Alone—0/22 (0%)15/22 (68.2%)
Humulin-R + rHuPH20—0/22 (0%)18/22 (81.8%)
Humulin-R Alone—0/21 (0%)18/21 (85.7%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventHumalog + rHuPH20Humalog AloneHumulin-R + rHuPH20Humulin-R Alone
Blood glucose decreasedInvestigations13/2211/2214/2214/21
HypoglycaemiaMetabolism and nutrition disorders5/224/229/227/21
HeadacheNervous system disorders1/223/223/221/21
Injection site erythemaGeneral disorders0/220/222/220/21
Viral infectionInfections and infestations0/220/220/221/21
Joint sprainInjury, poisoning and procedural complications0/220/220/221/21
Musculoskeletal painMusculoskeletal and connective tissue disorders0/220/221/221/21
NauseaGastrointestinal disorders0/221/220/220/21
VomitingGastrointestinal disorders0/221/221/220/21
Upper respiratory tract infectionInfections and infestations0/221/220/220/21

Baseline characteristics

All participants who received at least 1 dose of Humalog, Humulin-R, or recombinant human hyaluronidase PH20 (rHuPH20).

Age, Continuous
Age, Continuous(years)Overall Study
Mean40.7 ± 10.73
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female7
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino4
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White19
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Overall Study
United States22
08

Study locations

1 site
  • Profil Institute for Clinical Research, Inc.
    Chula Vista, California 91911, United States
09

References and documents

Publications

  • Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care. 2011 Mar;34(3):666-8. doi: 10.2337/dc10-1892. Epub 2011 Jan 27. PubMed 21273493 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2008
First posted
Oct 17, 2008
Start
Oct 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Sep 5, 2014
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00774800
Responsible party
Sponsor
First posted
Oct 17, 2008
Start date
Oct 2008
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Sep 5, 2014
Last update
Feb 26, 2019

Study contacts

Linda A Morrow, M.D.
principal investigator · Profil Institute for Clinical Research, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Insulin, Regular, Human · Hyaluronidase (human recombinant)

Start the discussion